158 related articles for article (PubMed ID: 28125374)
1. The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
MacEwan JP; Yin W; Kaura S; Khan ZM
J Manag Care Spec Pharm; 2017 Feb; 23(2):206-213. PubMed ID: 28125374
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
5. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
7. Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Bullock A; Rowan CG; Oestreicher N; Yeganegi H; Chiorean EG
J Manag Care Spec Pharm; 2020 Jul; 26(7):872-878. PubMed ID: 32584677
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Abraham I
Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
10. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL
Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
[TBL] [Abstract][Full Text] [Related]
15. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z
BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232
[TBL] [Abstract][Full Text] [Related]
17. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
Gut Liver; 2018 Nov; 12(6):728-735. PubMed ID: 30400731
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Chan KKW; Guo H; Cheng S; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM; Mittmann N; Coburn N; Arias J; Schwartz D; Dai WF; Gavura S; McLeod R; Kennedy ED
Cancer Med; 2020 Jan; 9(1):160-169. PubMed ID: 31724340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
